A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 6,790 shares of BIIB stock, worth $1.33 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
6,790
Previous 6,974 2.64%
Holding current value
$1.33 Million
Previous $1.5 Million 4.72%
% of portfolio
0.08%
Previous 0.08%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$190.52 - $236.72 $35,055 - $43,556
-184 Reduced 2.64%
6,790 $1.57 Million
Q1 2024

Apr 17, 2024

SELL
$212.02 - $267.71 $19,717 - $24,897
-93 Reduced 1.32%
6,974 $1.5 Million
Q4 2023

Jan 10, 2024

BUY
$222.59 - $267.94 $71,006 - $85,472
319 Added 4.73%
7,067 $1.83 Million
Q3 2023

Oct 27, 2023

BUY
$253.3 - $285.89 $398,440 - $449,704
1,573 Added 30.4%
6,748 $1.73 Million
Q2 2023

Aug 09, 2023

BUY
$275.25 - $318.06 $745,652 - $861,624
2,709 Added 109.85%
5,175 $1.47 Million
Q1 2023

Apr 20, 2023

BUY
$256.56 - $292.34 $96,466 - $109,919
376 Added 17.99%
2,466 $686,000
Q4 2022

Jan 12, 2023

BUY
$252.44 - $306.72 $527,599 - $641,044
2,090 New
2,090 $579,000
Q2 2022

Jul 19, 2022

SELL
$187.54 - $223.02 $205,356 - $244,206
-1,095 Closed
0 $0
Q1 2022

Apr 26, 2022

SELL
$193.77 - $244.14 $109,092 - $137,450
-563 Reduced 33.96%
1,095 $231,000
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $103,451 - $132,949
-462 Reduced 21.79%
1,658 $398,000
Q3 2021

Nov 12, 2021

BUY
$282.99 - $369.05 $29,147 - $38,012
103 Added 5.11%
2,120 $600,000
Q2 2021

Aug 13, 2021

SELL
$259.0 - $414.71 $87,542 - $140,171
-338 Reduced 14.35%
2,017 $698,000
Q1 2021

May 17, 2021

BUY
$242.95 - $284.63 $572,147 - $670,303
2,355 New
2,355 $659,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $28.2B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Hennion & Walsh Asset Management, Inc. Portfolio

Follow Hennion & Walsh Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.